Translational Development Acquisition (TDACU) Other Accumulated Expenses (2024 - 2026)

Translational Development Acquisition has reported Other Accumulated Expenses for 3 years, with the latest figure at $136762.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 509.92% year-over-year to $136762.0; the trailing twelve-month figure through Mar 2026 stood at $136762.0 (up 509.92% YoY), and the FY2025 full-year result was $106762.0, up 5238.1% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $136762.0, up from $106762.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $136762.0 in Q1 2026, with the low at $2000.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $65245.2 across 3 years, with a median of $61762.0 in 2025.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses surged 5238.1% — and 2026, when it soared 509.92%.
• Translational Development Acquisition's Other Accumulated Expenses stood at $2000.0 in 2024, then surged by 5238.1% to $106762.0 in 2025, then rose by 28.1% to $136762.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $136762.0 (Q1 2026), $106762.0 (Q4 2025), and $76762.0 (Q3 2025), per Business Quant data.